Are FLT3 inhibitors the mainstay of Midostaurin?

Midostaurin is a multi-target tyrosine kinase inhibitor, one of its most important functions is to inhibit FLT3 (FMS-like tyrosine kinase3). FLT3 mutations, especially FLT3-ITD mutations, are common genetic abnormalities in acute myeloid leukemia (AML) and are closely related to disease progression and poor prognosis. Therefore, midostaurin, as a FLT3 inhibitor, is one of the first-line targeted therapies for this type of mutation.

Midostaurin is commonly used clinically in newly diagnosed FLT3 mutation-positive AML patients, usually in combination with standard chemotherapy (cytarabine and daunorubicin). Multiple studies have shown that midostaurin combined with chemotherapy can not only significantly prolong overall survival, but also improve the complete remission rate. This result has prompted it to become a standard treatment option for patients with FLT3 mutated AML and has been recommended as a first-line treatment option by multinational guidelines.

Although midostaurin is an FLT3 inhibitor, its effect is not limited to FLT3, it can also target KIT and PDGFR, so they are classified as first-generation multi-target FLT3 inhibitors. This broad-spectrum inhibitory property not only brings it the possibility of treating a variety of hematological malignancies, but also means that compared with the new generation of more selective FLT3 inhibitors (such as giritinib), it has a wider spectrum of side effects, and some patients may have more complex tolerance issues.

In general, midostaurin is one of the main drugs currently used in the clinical treatment of FLT3mutationsAML, especially for patients with new onset and carrying FLT3 mutations. Although its multi-target mechanism brings certain risks of side effects, it still has important value in the treatment of complex AML conditions. In the future, with the development of second-generation, more targeted FLT3 inhibitors, midostaurin may become more of an important component of combination or early treatment regimens.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html